Saturday, November 7, 2020
- 11:30AM-1:00PM
-
Abstract Number: 0935
Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Trial of BIIB059, an Anti-Blood Dendritic Cell Antigen 2 Antibody, in SLE
Plenary Session II (0934–0939)- 11:30AM-1:00PM
-
Abstract Number: 0937
Late Cardiovascular Outcomes in Children with Kawasaki Disease: A Population-based Cohort Study
Plenary Session II (0934–0939)- 11:30AM-1:00PM
-
Abstract Number: 0938
Low Preconceptional Complement Level Is Related with an Adverse Obstetric Outcome in a Multicentric Cohort of Pregnancy in Patients with APS and aPL Positivity
Plenary Session II (0934–0939)- 11:30AM-1:00PM
-
Abstract Number: 0939
Maintenance of Remission After Withdrawal of Etanercept or Methotrexate in Patients with Rheumatoid Arthritis in Sustained Remission on Combination Therapy: Results from a Randomized, Double-blind, Controlled Trial
Plenary Session II (0934–0939)- 11:30AM-1:00PM
-
Abstract Number: 0936
Urine Proteomics and Single Cell Transcriptomics Identify IL-16 as a Biomarker for Lupus Nephritis
Plenary Session II (0934–0939)- 11:30AM-1:00PM
-
Abstract Number: 0934
Warfarin Use and Risk of Knee and Hip Replacements
Plenary Session II (0934–0939)- 3:00PM-3:50PM
-
Abstract Number: 0986
BIIB059, a Humanized Monoclonal Antibody Targeting Blood Dendritic Cell Antigen 2 on Plasmacytoid Dendritic Cells, Shows Dose-Related Efficacy in a Phase 2 Study in Participants with Active Cutaneous Lupus Erythematosus
SLE – Treatment (0985–0989)- 3:00PM-3:50PM
-
Abstract Number: 0978
Border-associated Macrophages Drive Recruitment of Immune Cells into the Choroid Plexus in Mice with Neuropsychiatric Lupus
SLE – Animal Models (0975–0979)- 3:00PM-3:50PM
-
Abstract Number: 0985
Early and Sustained Reduction in Severity of Skin Disease with Anifrolumab Treatment in Patients with Active SLE Measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI): Pooled Data from 2 Phase 3 Studies
SLE – Treatment (0985–0989)- 3:00PM-3:50PM
-
Abstract Number: 0987
Efficacy and Safety of Iberdomide in Patients with Active Systemic Lupus Erythematosus: 24-Week Results of a Phase 2, Randomized, Placebo-Controlled Study
SLE – Treatment (0985–0989)- 3:00PM-3:50PM
-
Abstract Number: 0977
Expanded T Peripheral Helper Cells and Increased Pathologic B Cell Lung Infiltration in Pristane-induced Murine Lupus in the Absence of BCL6+ Tfh Cells
SLE – Animal Models (0975–0979)- 3:00PM-3:50PM
-
Abstract Number: 0975
Gasdermin D Modulates Murine Lupus and Its Associated Organ Damage